Diabetes and heart failure share common metabolic pathways. Comprehensive structural, hemodynamic, and functional assessment using imaging and biomarkers is essential to identify risk, guide phenotype classification, and optimize cardioprotective management. 1 The latest recommendations frame care within primary and secondary prevention across the full cardiometabolic spectrum—from obesity and metabolic syndrome to diabetes, ASCVD, CKD, and heart failure.
Early and intensive intervention aims to prevent comorbidities, slow disease progression, reduce morbidity and mortality, and overcome clinical inertia to improve patient outcomes and adherence. 2 Join us for a high-impact clinical webinar on 7th March 2026 at 8:00 PM IST , where leading experts in cardiology and endocrinology will decode the evolving paradigm of cardiometabolic risk reduction in Type 2 Diabetes. This session will…
